Also from this source

You just read:

BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic

News provided by

BioAtla, LLC

Jun 28, 2018, 06:00 ET